CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MaxWell Biosystems is developing In-Cytes, an innovative platform for assessing neural connectivity in drug discovery. This technology aims to improve the understanding of brain diseases by providing high-resolution measurements of direct neural connections, addressing the pharmaceutical industry's need for effective d…
MaxWell Biosystems AG (MxW) is a Swiss public limited company (AG) who developed electrophysiological platforms (hardware-software-bioassays) for basic research and drug testing on nerve cells.
MxW’s aim is to develop In-Cytes, a radically innovative electrophysiology platform to assess neural connectivity for preclinical drug discovery for brain diseases.
In contrast to the state-of-the-art technologies for quantifying neural connectivity, which either estimate indirect connectivity or feature…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
